FDMT (4D Molecular Therapeutics) Total Equity: $451.84 Mil (As of Mar. 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.60
GF Value $214.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Total Equity?

4D Molecular Therapeutics FDMT +0.69% 55 Total Equity is $451.84 Mil as of Mar. 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.49 (Possible Value Trap). The stock has 6 warning signs investors should review.

4D Molecular Therapeutics's total equity for the quarter that ended in Mar. 2026 was $451.84 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

4D Molecular Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Total Equity Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 319.11 231.34 307.83 510.61 505.66

4D Molecular Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 469.72 420.89 368.98 505.66 451.84
FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

4D Molecular Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=566.711-61.047
=505.66

4D Molecular Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=512.905-61.069
=451.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $451.84 Mil mean?
4D Molecular Therapeutics (FDMT) has a Total Equity of $451.84 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for 4D Molecular Therapeutics and its competitors.
Is 4D Molecular Therapeutics' Total Equity too high?
4D Molecular Therapeutics' current Total Equity is $451.84 Mil. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Total Equity compare to KYTX and XOMA?
4D Molecular Therapeutics' Total Equity of $451.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Total Equity is $451.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.49, compared to a current price of $11.60 — trading 94.6% below its estimated fair value. The current Total Equity is $451.84 Mil. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Total Equity is $451.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.60 is trading 94.6% below its estimated GF Value™ of $214.49. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Total Equity: $451.84 Mil
  • GF Value™: $214.49 vs. price of $11.60 (94.6% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.60
Price
$214.49
GF Value